Article Details

BMO says Keytruda 'still reigns' after ivonescimab survival data | Markets Insider

Retrieved on: 2025-04-26 03:20:56

Tags for this article:

Click the tags to see associated articles and topics

BMO says Keytruda 'still reigns' after ivonescimab survival data | Markets Insider. View article details on hiswai:

Excerpt

However, BMO believes investors “may be over reading into the impact” to BioNTech shares, since the dataset is only an interim analysis. “On balance ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo